Contact
searchSearch
HMP Global
Login

News

Ibrahim Aldoss, MD
Videos
Azacitidine Plus Venetoclax Shows Superior Efficacy Compared With Intensive Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
01/12/2026
Ibrahim Aldoss, MD
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared...
01/12/2026
Oncology
News
Decitabine Plus Cedazuridine Maintenance Therapy Shows Promising Survival Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndromes
01/12/2026
Emily Estrada
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine...
01/12/2026
Oncology
News
Venetoclax Plus CACAG Regimen Demonstrates High Response Rates and Favorable Survival for R/R Acute Myeloid Leukemia
01/12/2026
Emily Estrada
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax...
01/12/2026
Oncology
News
Chidamide Plus Azacitidine Maintenance Demonstrates Promising Activity for Preventing Relapse After alloHSCT for Patients With High-Risk AML
12/01/2025
Emily Estrada
The combination of chidamide and azacitidine after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia demonstrated potential efficacy and acceptable toxicity in a phase 2 trial.
The combination of chidamide and azacitidine after allogeneic hematopoietic stem cell transplantation for patients with high-risk acute myeloid leukemia demonstrated potential efficacy and acceptable toxicity in a phase 2 trial.
The combination of chidamide and...
12/01/2025
Oncology
News
Autologous Stem Cell Transplantation Shows Improved Relapse-Free Survival Benefit Over Chemotherapy for AML Consolidation Therapy
12/01/2025
Emily Estrada
Among patients with acute myeloid leukemia in first remission, autoSCT showed significantly improved relapse-free and overall survival compared with chemotherapy according to a real-world, retrospective study.
Among patients with acute myeloid leukemia in first remission, autoSCT showed significantly improved relapse-free and overall survival compared with chemotherapy according to a real-world, retrospective study.
Among patients with acute...
12/01/2025
Oncology
FDA Approval
FDA Approves Ziftomenib for Patients With Relapsed/Refractory NPM1-Mutated Acute Myeloid Leukemia
11/13/2025
Emily Estrada
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a menin inhibitor, for patients with relapsed/refractory acute myeloid leukemia who have an NPM1 mutation and have no satisfactory alternative treatment options.
The FDA approved ziftomenib, a...
11/13/2025
Oncology
News
Enasidenib Plus Venetoclax Demonstrates Promising Activity for Relapsed/Refractory IDH2-Mutant AML: ENAVEN-AML Trial
10/30/2025
Emily Estrada
According to results from the ENAVEN-AML trial, enasidenib combined with venetoclax demonstrated clinical activity and manageable safety for R/R IDH2-mutated acute myeloid leukemia.
According to results from the ENAVEN-AML trial, enasidenib combined with venetoclax demonstrated clinical activity and manageable safety for R/R IDH2-mutated acute myeloid leukemia.
According to results from the...
10/30/2025
Oncology
FDA Approval
FDA Grants Approval to Revumenib for Patients With R/R NPM1-Mutated Acute Myeloid Leukemia
10/24/2025
Emily Estrada
The US Food and Drug Administration has approved revumenib for the treatment of relapsed/refractory acute myeloid leukemia for patients with an NPM1 mutation.
The US Food and Drug Administration has approved revumenib for the treatment of relapsed/refractory acute myeloid leukemia for patients with an NPM1 mutation.
The US Food and Drug...
10/24/2025
Oncology
News
PD-1 Inhibitor Plus Azacitidine and HAG Regimen Demonstrates Promising Activity for R/R Acute Myeloid Leukemia
10/02/2025
Emily Estrada
According to a phase 2 trial, a PD-1 inhibitor combined with azacitidine and homoharringtonine, cytarabine, and G-CSF therapy demonstrated promising efficacy and safety among patients with relapsed/refractory acute myeloid leukemia.
According to a phase 2 trial, a PD-1 inhibitor combined with azacitidine and homoharringtonine, cytarabine, and G-CSF therapy demonstrated promising efficacy and safety among patients with relapsed/refractory acute myeloid leukemia.
According to a phase 2 trial, a...
10/02/2025
Oncology
News
Ruxolitinib and Decitabine With Modified Busulfan/Cyclophosphamide Conditioning Treatment Tolerable, Reduces Relapse for High-Risk AML/MDS
10/02/2025
Emily Estrada
Additional ruxolitinib to decitabine with modified busulfan/cyclophosphamide therapy, showed promising relapse reduction and tolerability for high-risk acute myeloid leukemia and myelodysplastic syndrome with increased blasts treatment.
Additional ruxolitinib to decitabine with modified busulfan/cyclophosphamide therapy, showed promising relapse reduction and tolerability for high-risk acute myeloid leukemia and myelodysplastic syndrome with increased blasts treatment.
Additional ruxolitinib to...
10/02/2025
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use